GISAID is open-access to genetic data of influenza viruses, and the coronavirus responsible for the COVID-19 pandemic.
On January 10, 2020, the first whole-genome sequences of SARS-CoV-2 were made available on GISAID. This enabled global responses to the pandemic. There was the first vaccines, and diagnostic tests, to detect SARS-CoV-2. GISAID helps watch for the emergence of new COVID-19 viral strains across the planet.
Its establishment was an alternative to sharing avian influenza data by conventional public-domain archives. GISAID has given rapid exchange of outbreak data during the H1N1pandemic in 2009, the H7N9 epidemic in 2013, and the COVID-19pandemic in 2020.
GISAID was recognized for its importance to world health by G20 health ministers in 2017, and in 2020 the World Health Organization chief scientist called the data-science initiative "a game changer".
↑"Governance & Expertise: Scientific Advisory Council". GISAID. 2020. Retrieved July 7, 2020. The Scientific Advisory Council (SAC) comprises leading influenza scientists with expertise in epidemiology, human and veterinary virology and bioinformatics.
↑Polack, Fernando (December 10, 2020). "Safety and Efficacy of the mRNA Covid-19 Vaccine". New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMC7745181. PMID33301246. The development of BNT162b2 was initiated on January 10, 2020, when the SARS-CoV-2 genetic sequence was released by the Chinese Center for Disease Control and Prevention and disseminated globally by the GISAID (Global Initiative on Sharing All Influenza Data) initiative.